Watch the EASD 2018 Data disclosure session

CARMELINA: official trial data disclosure by members of the trial steering committee

CARMELINA:
a unique trial investigating the long-term CV and kidney safety profile of linagliptin versus placebo

Why do we need the CARMELINA trial?

International guidelines now recommend therapies with a proven CV benefit profile to be used preferentially in patients with T2D and CV disease, marking a new era in diabetes management1–3

Reducing the risk of CV and kidney complications is an important treatment goal in patients with T2D, who are at increased risk of these events4–6

However, a need remains for additional glucose-lowering medications with a proven long-term CV safety profile, and DPP-4 inhibitors represent a common add-on treatment choice2,3

The CARMELINA (CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with type 2 diabetes at high vascular risk) CVOT investigated the long-term CV and kidney safety profile of linagliptin versus placebo, on top of standard of care7

CARMELINA was a multinational, randomised, double-blind, placebo-controlled CVOT7

Study medication was given on top of stable background glucose-lowering therapy and patients were treated for CV risk factors in accordance with local guidelines

CARMELINA was specifically designed to evaluate the CV (3P-MACE) and kidney safety profile of linagliptin7

The CV safety profile of linagliptin was assessed using 3P-MACE (CV death, non-fatal MI, non-fatal stroke)

CARMELINA is the first CVOT to specifically assess the kidney safety profile of a DPP-4 inhibitor

CARMELINA studied a patient population that is relevant to clinical practice7

  • CARMELINA was designed to recruit patients with T2D, including those with CV and/or kidney disease: a population that has previously been underrepresented in other CVOTs in diabetes

The characteristics of patients enrolled in CARMELINA are representative of those seen in clinical practice...

    ...and the trial included patients across a broad range of kidney function and had a high proportion of patients with kidney disease

CARMELINA confirmed the long-term CV and kidney safety profile of linagliptin7

Cardiovascular

Long-term CV safety profile demonstrated

The 3P-MACE primary outcome occurred in 434/3494 (12.4%) and 420/3485 (12.1%) patients in the linagliptin and placebo groups, respectively

Hospitalisation for
heart failure

No increased risk of hospitalisation for heart failure

Rates of hospitalisation for heart failure did not differ between treatment groups: 209/3494 (6.0%) and 226/3485 (6.5%) in the linagliptin and placebo groups, respectively

Kidney

Long-term kidney safety profile demonstrated

The key kidney outcome§ occurred in 327/3494 (9.4%) and
306/3485 (8.8%) patients in the linagliptin and placebo groups, respectively

Overall safety

CARMELINA reaffirmed the overall safety profile of linagliptin

What is the meaning of the CARMELINA results?7

In CARMELINA, linagliptin demonstrated a long-term CV safety profile in patients with T2D, including those with
CV and/or kidney disease

Linagliptin showed no increase in risk of hospitalisation for heart failure, even in patients at high risk of heart failure

Linagliptin demonstrated a reassuring long-term kidney safety profile

CARMELINA thus provides unique clinical evidence for a patient population that is highly relevant to clinical practice

Want to know more about the CARMELINA trial? Click here for further resources

For information on the CAROLINA trial, please click here

Logo Carmelina
Logo Carolina
A robust CVOT programme assessing the long-term
CV and kidney safety profile of linagliptin
*Linagliptin patients only;7 Time to first occurrence of CV death, non-fatal MI or non-fatal stroke;7 Because the tests for superiority of the primary outcome (3P-MACE) and the key secondary outcome (composite kidney outcome) in the overall population were not met (p=0.74 and p=0.62 for superiority, respectively), all other analyses and outcomes are considered exploratory;7 §Time to first occurrence of sustained eGFR decrease by ≥40%, progression to sustained ESKD or death due to kidney disease (key secondary outcome)7
3P-MACE, 3-point major adverse cardiovascular events; CV, cardiovascular; CVOT, cardiovascular outcomes trial; DPP-4, dipeptidyl peptidase-4; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease; MI, myocardial infarction; T2D, type 2 diabetes
1. Diabetes Canada Clinical Practice Guidelines Expert Committee. Can J Diabetes 2018;42:S162; 2. American Diabetes Association. Diabetes Care 2020;43:S1; 3. Buse JB et al. Diabetes Care 2020;43:487; 4. Sarwar N et al. Lancet 2010;375:2215; 5. Thomas M et al. Nat Rev Nephrol 2016;12:73; 6. Diabetes Canada. Can J Diabetes 2018;42:S201; 7. Rosenstock J et al. JAMA 2019;321:69

©2020 Boehringer Ingelheim International GmbH. All rights reserved.